Soleno Therapeutics (SLNO) Cash from Discontinued Operations (2016 - 2018)

Soleno Therapeutics (SLNO) has 3 years of Cash from Discontinued Operations data on file, last reported at 188000.0 in Q4 2018.

• On a quarterly basis, Cash from Discontinued Operations rose 66.61% year-over-year to 188000.0 in Q4 2018; TTM through Dec 2018 was 1361000.0, a 55.1% increase from a year earlier, with the FY2018 full-year figure at 1361000.0, up 55.1% from the prior year.
• Cash from Discontinued Operations for Q4 2018 stood at 188000.0, up from 405000.0 in the prior quarter.
• Over the last five years, Cash from Discontinued Operations for SLNO reached as high as 188000.0 in Q4 2018 and fell as low as 2783000.0 in Q3 2016.
• Historically, Cash from Discontinued Operations has averaged 855927.2 across 3 years, with a median of 648000.0 in 2017.
• Across the five-year window, Cash from Discontinued Operations soared 73.66% in 2017 and jumped 41.61% in 2018, its largest moves.
• Year by year, Cash from Discontinued Operations stood at 1384272.0 in 2016, then soared by 59.33% to 563000.0 in 2017, then surged by 66.61% to 188000.0 in 2018.
• Per Business Quant data, the three most recent Cash from Discontinued Operations figures were 188000.0 in Q4 2018, 405000.0 in Q3 2018, and 281000.0 in Q2 2018.